Role of miRNA in Lung Cancer-Potential Biomarkers and Therapies

E-ISSN： 1873-4286|23|39|5997-6010

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.23, Iss.39, 2018-02, pp. : 5997-6010

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

MicroRNAs (miRNAs) are small noncoding RNAs, which downregulate gene expression by repressingor degrading mRNA targets. Lung cancer (LC), together with liver and colorectal cancers are the three leadingcauses of cancer death worldwide, and 80% of LCs belong to non-small cell lung cancers (NSCLCs). Despitea great advancement in developing distinct and delicate tools for early diagnosis and targeted therapies over thelast decade, only about 15% of the NSCLC patients eventually survived. MiRNAs are frequently dysregulated incarcinoma, including LC. Numerous lines of evidence have demonstrated various roles played by miRNAs in thedevelopment and progression of LC. In this review, we propose to summarize the current understanding of miRNAsin LC, with a particular focus on translational application of miRNAs as novel diagnostic and prognosticbiomarkers and tools for treatment.